BioSpace News Archive

Policy

U.S. Government Seeks $12 Billion in Opioid-Related Damages from Purdue Pharma

The U.S. government is seeking $11 billion in civil and criminal penalties from Purdue Pharma as the maker of OxyContin winds its way through bankruptcy.

August 5, 2020
·
3 min read
·
Alex Keown
Genetown

GentiBio Launches with $20 Million Seed Funding from Novartis and Others

GentiBio focuses on engineered regulatory T-cells (EngTregs) to treat autoimmune, alloimmune, autoinflammatory and allergic diseases.

August 5, 2020
·
3 min read
·
Mark Terry
Business

Versant Ventures Launches Oncology-Focused Matterhorn Biosciences

With a $30 million investment, Versant Ventures launches Matterhorn Biosciences AG, a company developing T cell receptor therapies based on the recent discovery of MR1-restricted T (MRIT) cells that recognize and kill a wide range of tumors of various tissue origins.

August 5, 2020
·
2 min read
·
Alex Keown
Drug Development

COVID-19 Vaccine Trials: Minority Concerns and Issues

Several polls have suggested that as much as half of the U.S. population is unlikely to get the vaccine for a variety of reasons, including not feeling it is safe.

August 5, 2020
·
4 min read
·
Mark Terry
BioMidwest

Two Mass-Market, Paper-based COVID-19 Diagnostics Tests in Development

Researchers are developing simpler COVID-19 diagnostic tests for use outside of labs in an effort to make mass testing available, fast and inexpensive.

August 5, 2020
·
4 min read
·
Gail Dutton
BioSpace Global Roundup, Aug. 6

Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.

August 5, 2020
·
6 min read
·
Alex Keown
Drug Development

Companies and Institutions Asked to Publicize Years Worth of Clinical Trial Data

According to a warning from federal officials last week, dozens of drug companies, universities and medical device manufacturers owe more than a decade’s worth of data from clinical trials.

August 5, 2020
·
2 min read
·
Krystle Vermes
Drug Development

Novavax’s COVID-19 Vaccine Phase I Trial Hits the Mark, Shows Promise

The company announced data from Phase I of its Phase I/II placebo-controlled trial of its vaccine with and without Matrix-M adjuvant.

August 5, 2020
·
3 min read
·
Mark Terry
Bio NC

United Therapeutics Corporation to Present at the Wedbush PacGrow Healthcare Virtual Conference

United Therapeutics Corporation announced that Dr. Martine Rothblatt, Chairman and Chief Executive Officer of United Therapeutics, will provide an overview and update on the company’s business during a fireside chat session at the Wedbush PacGrow Healthcare Virtual Conference.

August 5, 2020
·
2 min read
BioCapital

Cystic Fibrosis Foundation and Longwood Fund Launch CF Incubator

The Cystic Fibrosis Foundation announced a collaboration with Longwood Fund, a biotech-focused venture capital firm, to accelerate innovative therapies for cystic fibrosis.

August 5, 2020
·
4 min read